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Abstract
Background: The Leishmania OligoC-TesT and NASBA-Oligochromatography (OC) were recently developed for simplified
and standardised molecular detection of Leishmania parasites in clinical specimens. We here present the phase II evaluation
of both tests for diagnosis of visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and post kala-azar dermal
leishmaniasis (PKDL) in Sudan.
Methodology: The diagnostic accuracy of the tests was evaluated on 90 confirmed and 90 suspected VL cases, 7 confirmed
and 8 suspected CL cases, 2 confirmed PKDL cases and 50 healthy endemic controls from Gedarif state and Khartoum state
in Sudan.
Principal Findings: The OligoC-TesT as well as the NASBA-OC showed a sensitivity of 96.8% (95% CI: 83.8%–99.4%) on
lymph node aspirates and of 96.2% (95% CI: 89.4%–98.7%) on blood from the confirmed VL cases. The sensitivity on bone
marrow was 96.9% (95% CI: 89.3%–99.1%) and 95.3% (95% CI: 87.1%–98.4%) for the OligoC-TesT and NASBA-OC,
respectively. All confirmed CL and PKDL cases were positive with both tests. On the suspected VL cases, we observed a
positive OligoC-TesT and NASBA-OC result in 37.1% (95% CI: 23.2%–53.7%) and 34.3% (95% CI: 20.8%–50.9%) on lymph, in
72.7% (95% CI: 55.8%–84.9%) and 63.6% (95% CI: 46.6%–77.8%) on bone marrow and in 76.9% (95% CI: 49.7%–91.8%) and
69.2% (95% CI: 42.4%–87.3%) on blood. Seven out of 8 CL suspected cases were positive with both tests. The specificity on
the healthy endemic controls was 90% (95% CI: 78.6%–95.7%) for the OligoC-TesT and 100% (95% CI: 92.9%–100.0%) for the
NASBA-OC test.
Conclusions: Both tests showed high sensitivity on lymph, blood and tissue scrapings for diagnosis of VL, CL and PKDL in
Sudan, but the specificity for clinical VL was significantly higher with NASBA-OC.
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Introduction
The leishmaniases are a group of vector-borne diseases caused
by parasites of the genus Leishmania. The parasites are transmitted
by phlebotomine sand flies and can cause, depending on the
infecting species, three main clinical manifestations of leishman-
iasis: visceral leishmaniasis (VL), post kala-azar dermal leishman-
iasis (PKDL) and cutaneous leishmaniasis (CL) including the
mucocutaneous form [1]. VL is the most severe form in which the
internal organs are invaded and tends to be 100% fatal if not
appropriately treated. While CL and MCL are clinical manifes-
tations as a result from replication of the parasite in the dermis and
naso-oropharyngeal mucosa respectively, PKDL is a skin disorder
seen in a number of treated VL patients. VL, PKDL and CL are
endemic in several parts of Sudan and especially VL represents a
major health problem in this country [2].
Although serological tests such as the direct agglutination test
(DAT) [3,4] and the rK39 dipstick test [5–7] have become the
mainstay in VL diagnosis [8], parasite detection by microscopic
analysis of aspirates from the lymph nodes, bone marrow or spleen
is still used in some endemic regions. The diagnostic standard for
CL and PKDL is microscopic analysis of tissue biopsies or
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variable sensitivity and the need for rather invasive sampling in the
case of VL. Sensitivity may be increased by prior in vitro cultivation
of the parasite, but this technique is cumbersome and time
consuming. Serological tests are of high value to support clinical
diagnosis of VL but they are less useful in patients co-infected with
HIV [9] and antibodies remain detectable for years after successful
treatment [10,11]. Antibody detection with the rapid rK39
dipstick test is not yet implemented in Sudan due to the reported
low diagnostic performance of the test in this region [12–14].
Molecular diagnostics such as the polymerase chain reaction
(PCR) and nucleic acid sequence based assay (NASBA) offer
attractive alternatives to conventional parasite detection as they
are generally highly sensitive and specific. PCR detects the
parasite’s DNA through in vitro thermocyclic conditions [15], while
NASBA amplifies the RNA by an isothermal reaction [16].
However, broad application of these powerful techniques in
diagnosis and control of leishmaniasis is hindered by their
complexity and lack of standardised test formats. Recently, the
Leishmania OligoC-TesT and NASBA-Oligochromatography (OC)
were introduced as promising PCR and NASBA formats for
simplified and standardised molecular detection of Leishmania
parasites [17,18]. The tests are based on amplification of a short
sequence within the Leishmania 18S ribosomal DNA (PCR) or
RNA (NASBA), followed by simple and rapid detection of
amplified products in dipstick format. Both tests are available as
self-containing kits including all components needed except for the
Taq polymerase enzyme in the OligoC-TesT and the Nuclisense
Basic Kit in the NASBA-OC due to licensing issues. The tests
showed high sensitivity and specificity on experimentally prepared
specimens and on clinical specimens from a limited number of
confirmed cases and healthy controls (phase I) [17,18] and
satisfactory repeatability and reproducibility in a multicenter
evaluation study [19]. In this phase II study, we evaluated the two
tests in Sudan on confirmed and suspected VL, CL and PKDL
patients and on healthy endemic controls.
Methods
Participants
VL and PKDL suspects and endemic healthy controls were
recruited in Gedarif State and CL suspects in Khartoum State
between October 2008 and January 2009. VL and PKDL suspects
were recruited in the health centers of villages within the endemic
areas while the endemic healthy controls were volunteers from the
same villages but not visiting the health centers. CL suspects were
recruited at the Dermatology Hospital in Khartoum. Confirmed
leishmaniasis cases were given appropriate treatment in the same
health center or hospital as they were diagnosed. A participant was
included in the study if 2 years or older and written consent was
obtained from the individual or his/her guardian. Specimen
collection was performed by the Faculty of Medicine of Khartoum
University. Ethical clearance for the study was obtained from the
ethical committees of the Federal Ministry of Health Committee in
Sudan and the University of Antwerp in Belgium.
Participant classification and reference tests
A participant was classified as (i) confirmed VL case if there was
clinical suspicion for VL, DAT on serum was positive (titer
$1:3200) and parasites were observed in lymph or bone marrow
aspirates by microscopic analysis; (ii) suspected VL case with
positive DAT if there was clinical suspicion for VL, DAT on serum
was positive, no parasites were observed in lymph or bone marrow
aspirates and no previous history of VL was reported; (iii)
suspected VL case with negative DAT if there was clinical
suspicion for VL, DAT on serum was negative, no parasites were
observed in lymph or bone marrow aspirates and no previous
history of VL was reported; (iv) endemic healthy control if there
was no clinical suspicion for VL, no previous history of VL and
DAT on serum was negative; (v) confirmed CL or PDKL case if
there was clinical suspicion for CL or PKDL and parasites were
observed in lesion or skin scrapings by microscopic analysis; and
(vi) suspected CL case if there was clinical suspicion for CL and no
parasites were observed in lesion or skin scrapings. Clinical
suspicion for VL was defined as a history of fever for two weeks or
more and splenomegaly or lymphadenopathy and for CL and
PKDL the presence of skin lesions or nodules. The reference tests
were performed by experienced laboratory technicians immedi-
ately after specimen taking at the collection sites as described in the
WHO manual on visceral leishmaniasis [20].
Index tests
Two hundred ml anti-coagulated blood (confirmed and
suspected VL cases and healthy endemic controls), and/or
inguinal lymph node aspirate, and/or bone marrow aspirate
(confirmed and suspected VL cases) or lesion or skin scrapings
(confirmed and suspected CL and PKDL cases) was mixed with
200 ml of AngeroNA buffer (Mallinckrodt Baker, USA). This
buffer allows specimen storage without loss of DNA and RNA
quality. The same specimens were used for the reference tests and
for the index tests. Specimens were shipped at 4uC from the
collection site to Soba University hospital laboratory of Khartoum
University and stored at 4uC for a maximum of two weeks. Nucleic
acids of the specimens were extracted according to the method
described by Boom et al. [21]. Elution was done in 50 ml of Tris-
EDTA (TE) buffer and stored at 220uC until analysis. The
extracts were tested with the Leishmania OligoC-TesT and
NASBA-OC between October 2008 and February 2009 as
described by Deborggraeve et al. [17] and Mugasa et al. [18].
In brief, with the OligoC-TesT DNA of the parasite is amplified
by PCR and subsequently 40 ml of denatured PCR product is
mixed with 40 ml of migration buffer preheated at 55uC for at least
20 minutes followed by dipping the Oligo-strip into the solution.
The NASBA-OC amplifies an RNA sequence of the parasite by
NASBA reaction after which 4 ml of the amplified product is
mixed with 76 ml of migration buffer preheated at 55uC and the
Author Summary
The leishmaniases are a group of vector-borne diseases
caused by protozoan parasites of the genus Leishmania.
The parasites are transmitted by phlebotomine sand flies
and can cause, depending on the infecting species, three
clinical manifestations of leishmaniasis: visceral leishman-
iasis (VL), post kala-azar dermal leishmaniasis (PKDL) and
cutaneous leishmaniasis (CL) including the mucocutane-
ous form. VL, PKDL as well as CL are endemic in several
parts of Sudan, and VL especially represents a major health
problem in this country. Molecular tests such as the
polymerase chain reaction (PCR) or nucleic acid sequence
based assay (NASBA) are powerful techniques for accurate
detection of the parasite in clinical specimens, but broad
use is hampered by their complexity and lack of
standardisation. Recently, the Leishmania OligoC-TesT
and NASBA-Oligochromatography were developed as
simplified and standardised PCR and NASBA formats. In
this study, both tests were phase II evaluated for diagnosis
of VL, PKDL and CL in Sudan.
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10 minutes for both tests. Executors of the index tests were trained
during a one-week workshop held in June 2007 at Makerere
University, Kampala, Uganda. No external quality control
confirming the reference test or index test results could be
performed during the study. Executors of the index tests were not
blinded to the results of the reference tests.
Data analysis
The sensitivity and specificity of the Leishmania OligoC-TesT and
NASBA-OC were calculated from data entered into contingency
tables. Differences in sensitivity and specificity between the two tests
and differences in test results of specimen types were estimated by
the Mc Nemar test. Concordances between the two tests were
determined using the kappa index. All calculations were estimated
at a 95% confidence interval (95% CI).
Results
Participants
In the study the following participants were recruited: 90
confirmed and 67 suspected VL cases with positive DAT, 23
suspected VL cases with negative DAT, 7 confirmed and 8
suspected CL cases, 2 confirmed PKDL cases and 50 healthy
endemic controls.
Sensitivity and specificity of the Leishmania OligoC-TesT
and NASBA-OC
Confirmed VL, CL and PKDL patients. The Leishmania
OligoC-TesT and the NASBA-OC showed both a sensitivity of
96.8% on lymph node aspirates from confirmed VL cases and of
96.2% on blood (Table 1). The sensitivity on bone marrow was
96.9% and 95.3% for the OligoC-TesT and NASBA-OC,
respectively. All confirmed CL (n=7) and PKDL (n=2) cases
were positive with the OligoC-TesT and NASBA-OC. There was
no significant difference in sensitivity between the two index tests
(P.0.05). When analysing different specimen types from the same
VL patient we observed no significant difference in test outcome
(P.0.05).
Suspected VL and CL patients. On the suspected VL cases
with positive DAT, the OligoC-TesT showed a positive test result
in 37.1%, 76.9% and 72.7% on lymph, blood and bone marrow,
respectively; while for NASBA-OC this was 34.3%, 69.2% and
63.6% (Table 1). On the suspected VL cases with negative DAT,
the OligoC-TesT was positive in 30%, 28.6% and 42.9% on
lymph, blood and bone marrow and the NASBA-OC in 30%,
42.9% and 50%. On the 8 CL suspected cases 7 were positive with
the OligoC-TesT and the NASBA-OC. The Mc Nemar test
indicated no significant difference in results of the two tests on the
specimens from suspected cases (P.0.05). We observed no
Table 1. Diagnostic accuracy of the Leishmania OligoC-TesT and NASBA-OC on confirmed and suspected leishmaniasis cases and
on healthy endemic controls from Sudan.
Participants
Number of
specimens OligoC-TesT NASBA-OC
Number of
positives
Sensitivity
% (95% CI)
Specificity
% (95% CI)
Number of
positives
Sensitivity
% (95% CI)
Specificity
% (95% CI)
Confirmed cases
VL
Lymph 31 30 96.8 (83.8–99.4) 30 96.8 (83.8–99.4)
Blood 79 76 96.2 (89.4–98.7) 76 96.2 (89.4–98.7)
Bone marrow 64 62 96.9 (89.3–99.1) 61 95.3 (87.1–98.4)
CL
Lesion scrapings 7 7 100 (64.6–100) 7 100 (64.6–100)
PKDL
Skin scrapings 2 2 100 (34.2–100) 2 100 (34.2–100)
Suspected cases
Suspected VL with pos DAT
Lymph 35 13 37.1 (23.2–53.7) 12 34.3 (20.8–50.9)
Blood 13 10 76.9 (49.7–91.8) 9 69.2 (42.4–87.3)
Bone marrow 33 24 72.7 (55.8–84.9) 21 63.6 (46.6–77.8)
Suspected VL with neg DAT
Lymph 10 3 30 (10.8–60.3) 3 30 (10.8–60.3)
Blood 14 4 28.6 (11.7–54.7) 6 42.9 (24.4–67.4)
Bone marrow 14 6 42.9 (24.4–67.4) 7 50 (26.8–73.2)
CL
Lesion scrapings 8 7 87.5 (52.9–97.8) 7 87.5 (52.9–97.8)
Healthy endemic controls
Blood 50 5 90 (78.6–95.7) 0 100 (92.9–100)
Note. CI=confidence interval, VL=visceral leishmaniasis, CL=cutaneous leishmaniasis, PKDL=post kala azar dermal leishmaniasis, pos=positive, neg=negative,
DAT=direct agglutination test.
doi:10.1371/journal.pntd.0000776.t001
Oligochromatography Diagnostics in Sudan
www.plosntds.org 3 August 2010 | Volume 4 | Issue 8 | e776significant difference in test outcome when different specimen
types from the same suspected VL patient were analysed (P.0.05).
Healthy endemic controls. Five of the 50 healthy endemic
controls showed a positive OligoC-TesT result, while the NASBA-
OC remained negative on all endemic controls (Table 1). Hence,
the specificity of the OligoC-TesT for disease was 90.0% and of
the NASBA-OC 100.0%, which is significantly higher (P,0.05).
Test agreement. On all specimens analysed (n=321) the
two tests showed a kappa value of 0.85 (95% CI: 0.75–0.96)
indicating almost perfect agreement [22]. An overview of the
agreement analysis on the different specimen types is presented in
table 2.
Discussion
Molecular diagnostics are attractive alternatives to conventional
parasite detection as they combine sensitivity with specificity.
Recently, the Leishmania OligoC-TesT and NASBA-OC were
developed as standardised formats for molecular detection of
Leishmania parasites [17,18]. Here we present the phase II
evaluation of the two tests on confirmed and suspected VL, CL
and PKDL cases and on health endemic controls from Sudan.
Although the study was set out as a phase II diagnostic evaluation,
it has some limitations. A weak point is the lack of external quality
control on a subset of specimens carried out by another reference
laboratory. Furthermore, the executors of the index tests were not
blinded to the participant classification and thus the results of the
reference tests. Although we are convinced that these limitations
did not influence the study results, these shortcomings should be
avoided in future phase II and III evaluation trials. In addition,
response to treatment was not included in the standard references
as we were not able to follow up the patients after treatment.
Lastly, the number of participants in some subgroups is too low to
make major conclusions.
The Leishmania OligoC-TesT as well as the NASBA-OC showed
a high sensitivity (.95%) on lymph, blood and bone marrow from
the confirmed VL patients. The observation that analysing lymph
or blood yielded similar sensitivity as bone marrow is very
promising towards less invasive diagnosis. Indeed this means that
the OligoC-TesT and NASBA-OC on lymph or blood could
indicate the infection status of VL suspected cases. Similar findings
were reported in a study on the phase III evaluation of
conventional PCR for VL diagnosis in Nepal [23]. Although the
number of confirmed CL and PKDL cases in our study was
limited, all were positive with both tests indicating their potential
for accurate detection of the parasites in skin tissues. In addition,
the high sensitivity is confirmed by the observation that the tests
were able to detect Leishmania RNA or DNA in the blood or lesion
scrapings of to the majority of the suspected VL and CL cases.
Several cases in the suspected patient with positive DAT group
might be true leishmaniasis cases given the suboptimal sensitivity
of the conventional parasite detection tests. In 2008, Deborggraeve
et al. reported a sensitivity of conventional PCR on probable VL
cases (defined as clinical suspicion of VL and positive DAT test but
negative in conventional parasite detection) of 67.6% on blood
and 71.8% on bone marrow [23]. The sensitivities of the index
tests on the lymph node aspirates of the suspected VL cases is
surprisingly low (34–37%). This might indicate that the parasite
load in blood is higher than in lymph. The fact that this is not
observed in the confirmed VL cases is probably due to the general
higher parasite load in this patient group because of the low
sensitivity of the reference test. PCR positivity in the suspected VL
group with negative DAT was not significantly lower than with
positive DAT. This confirms the low correlation in DAT and PCR
status in these groups as observed earlier [23]. While antibody
levels in the blood are a marker for the host response, the PCR/
NASBA status of the blood is a marker for the presence of
parasites and might therefore be complementary. PCR and
NASBA can offer an added value compared to immunodiagnosis
in HIV co-infected VL patients.
On the 50 healthy endemic controls, the OligoC-TesT showed
a specificity of 90% while this was 100% for the NASBA-OC. The
positive OligoC-TesT results might be due to asymptomatic
infections, which are known to be common in VL endemic
regions. The inclusion of these asymptomatic carriers in the
control group could be explained by the low concordance between
negative DAT status and PCR outcome on blood from endemic
control persons as described by Deborggraeve et al. [23] and
Bhattarai et al. [24]. However, while NASBA-OC showed equal
sensitivity on the confirmed and suspected VL cases, the test did
not detect these assumed asymptomatic infections in the endemic
control group. This discrepancy can be explained in two ways.
Firstly, although not indicated by the negative controls taken along
in specimen analysis, contamination of the PCR can never be fully
excluded. Secondly, the OligoC-TesT might be slightly more
sensitive than the NASBA-OC and thus pick up asymptomatic
infections which might have very low parasite loads in the blood.
The observed equal sensitivity for both tests on the confirmed and
suspected VL cases might be biased by the fact that these cases are
individuals presenting syndromes and thus probably have higher
parasite loads than healthy parasite carriers. Hence, NASBA-OC
might provide a better marker for active disease than the OligoC-
TesT, as NASBA-OC does not detect asymptomatic infections
while more than 95% of the active VL cases are still positive with
the test. Furthermore, both tests might be useful as a test of cure
after treatment of VL. As cure does not always equals parasite
clearance, NASBA-OC might be more suitable than the OligoC-
TesT. However, specific evaluation studies are needed to confirm
this hypothesis.
Table 2. Agreement between the Leishmania OligoC-TesT and NASBA-OC on blood, lymph, bone marrow and lesion scraping
specimens.
Specimen type Number of specimens Number of specimens with agreement Kappa value (95% CI)
Blood 142 134 0.89 (0.72–1)
Lymph 66 59 0.77 (0.53–1)
Bone marrow 97 93 0.82 (0.63–1)
Lesion scrapings 17 17 1 (0.53–1.48)
Total 321 302 0.85 (0.75–0.96)
doi:10.1371/journal.pntd.0000776.t002
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are not yet an option for routine diagnosis at the primary care level
as they require basic molecular biology lab facilities. VL typically
affects populations in rural areas where health centers most often
suffer from infrastructural limitations and thus only apply less
sophisticated diagnostic methods. Yet, they can be valuable tools
in leishmaniasis diagnosis at reference hospitals with basic
molecular biology lab facilities. In addition, the evaluated tools
can offer an added value in disease surveillance and epidemiolog-
ical studies in which specimens are analysed at central reference
laboratories.
In conclusion, the Leishmania OligoC-TesT and NASBA-OC
showed high sensitivity on lymph and blood of VL patients and on
scrapings from CL and PKDL patients from Sudan. A significant
higher specificity for active VL with the NASBA-OC than with the
OligoC-TesT was observed. Both tests are not yet an option for
routine diagnosis of leishmaniasis at the primary care level due to
their infrastructural requirements but they might be powerful
diagnostic tests in disease surveillance programmes and in
monitoring intervention studies.
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